BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018
|
|
- Nicholas Hopkins
- 5 years ago
- Views:
Transcription
1 BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director
2 Forward Looking Statements This presenta8on may contain forward-looking statements with respect to the financial condi8on, results and business achievements/performance of Biotron Limited (ACN ) and certain of the plans and objec8ves of its management. These statements are statements that are not historical facts. Words such as should, expects, an8cipates, es8mates, believes or similar expressions, as they relate to Biotron Limited, are intended to iden8fy forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron s current expecta8ons and assump8ons as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assump8ons or expecta8ons could cause actual results to differ materially from current expecta8ons.
3 Biotron Snapshot Clinical stage anpviral drug development company with a promising pipeline of novel drug candidates targepng serious virus infecpons Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug in development for treatment of HIV-1 and HepaPPs C virus (HCV) Posi8ve data in trials to date HIV-1 Phase 2 trial complete; data an8cipated end 3Q18 Provides clinical validapon of Biotron s approach to treapng serious virus infecpons Robust pipeline of first-in-class an8viral programs Headquartered in Sydney, Australia Experienced Board and management team with pharma, financial and VC backgrounds
4 Biotron AnPviral Focused Pipeline PROGRAM MECHANISM OF ACTION INDICATION PRECLINICAL PHASE 1/2a PHASE 2 MARKET OPPORTUNITY BIT225 Targets HIV-1 Vpu viroporin protein Targets HCV p7 viroporin protein HIV-1 Hepatitis C virus Results expected end 3Q18 Ph 2 complete; seeking partnerships in China - ~$20 bn p.a. - >36 m living with HIV-1 ww m in USA - ~$20 bn p.a. - Es8mated m infected in China BIT314 Targets HCV p7 viroporin protein (next generapon) Hepatitis C virus Dengue Targets Dengue M viroporin protein Dengue bn live in at risk areas - ~100 m infec8ons p.a. - No drug treatment HBV, Respiratory & others Target specific virus virporin proteins HBV, Respiratory & others - Growing billion dollar markets
5 Biotron New Approach to AnP-Viral Drug Development Focused on the design and development of a new class of an8viral drugs targe8ng viralencoded viroporin proteins Viroporins are present in wide range of viruses: Influenza (M2), HIV-1 (Vpu), HCV (p7), Dengue and West Nile (M protein), SARS (E protein) and others Broad planorm: Rapid, proprietary primary bacterial cell-based screening assays for target proteins Focused library of compounds that target these viral proteins Pipeline of internally-generated, first-in-class small molecule viroporin inhibitors for key markets
6 HIV-1 EradicaPon HIV-1 remains hidden in reservoirs, leading to chronic, life-long infecpon Invisible to body s immune defenses Not sensi8ve to current an8-hiv-1 drugs New mode of ac8ons drugs are needed to eradicate or cure HIV-1 infec8on Why is HIV-1 eradicapon necessary? Long-term health implica8ons e.g. HAND, immune ac8va8on, drug-drug interac8ons Compliance/drug holidays can lead to viral rebound Cost of treatment ~ $20 billion p.a. world wide Major burden on healthcare systems
7 BIT225 Targets HIV-1 in Reservoir Cells BIT225 aoacks forma8on of new virus in macrophage reservoirs Phase 1b/2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in vivo, paralleling in vitro studies (Wilkinson et al, J An8microb Chemother. 2015) Poten8al to add BIT225 to current treatment to clear this source of virus and improve health A (A) Untreated Controls B (B) BIT225 treated cells
8 BIT Phase 2 HIV-1 Trial Subjects 36 HIV-posiJve, treatment-naïve subjects commencing standard anjretroviral treatment (ART) Protocol - Double-blind, placebo-controlled, randomised, mulj-centre study - 12 weeks, once daily, oral treatment with BIT225 or placebo in combinajon with ART Primary Objec3ve Secondary Objec3ve STATUS To determine whether the addijon of BIT225 impacts on reducjon of virus levels over and above ART To determine whether BIT225 has any impact on the immune system, which may indicate addijonal benefits of the drug in pajents Clinical component complete; detailed laboratory analyses of pajent samples in progress; data expected 3Q18
9 Investment ProposiPon BIT drugs target high growth, mulp-billion dollar markets with defined treatment gaps HIV-1 Program - Value inflec8on points around HIV-1 program data expected in late 3Q18 HCV Program - BIT225 par8cularly well suited to Asia, with high numbers of HCV-infected pa8ents including a high propor8on of HCV/HBV co-infected pa8ents Early stage commercial collabora8on opportuni8es for pre-clinical targets, such as: Hepa88s B Respiratory viruses Seeking partners for individual targets or en8re planorm
10 Financial InformaPon Key Financial Metrics Ticker Code ASX: BIT Share Price (15 Aug 18) A $0.017 Market cap A $9 million 12 Month Trading Range A $ $0.042 Shares Outstanding 502 million Cash Posi8on (June 18) A $1.54 million 12 Month Share Price Performance Ticker Code ASX: BIT Share Price (15 Sept 2014) A $0.115 Market cap A $26.3 million 12 Month Trading Range A $ Michael Hoy Board Non-execu8ve Chairman Shares Outstanding Cash Posi8on (06/14) 228 million A $1.76mn Michelle Miller Managing Director Susan Pond Non-execu8ve Director Rob Thomas Non-execu8ve Director
PRESENTATION AT BIOTECH INVEST 2016
4 May 2016 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website:
More informationBIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017
BIOTRON LIMITED (ASX:BIT) Biotech Showcase 2017 Forward Looking Statements This presenta,on may contain forward-looking statements with respect to the financial condi,on, results and business achievements/performance
More informationFor personal use only
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2016 The Manager Companies ASX Limited
More informationBIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 28 October 2013 The Manager Companies ASX Limited 20
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationBIOTRON LIMITED PRESENTS AT BIOTECH SHOWCASE TM 2016
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 12 January 2016 The Manager Companies ASX Limited 20
More informationRENOUNCEABLE RIGHTS ISSUE
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 25 May 2017 The Manager Companies ASX Limited 20 Bridge
More informationPRESENTATION TO INVESTORS. I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, to investors today.
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 11 November 2010 The Manager Companies ASX Limited
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationBioDiem to present at Hong Kong biotech investment forum
ASX Announcement BIODIEM LTD ABN 20 096 845 993 Suite 3, Level 11, 470 Collins Street, Melbourne, Victoria, 3000 Australia Phone: +613 9613 4100 Web: www.biodiem.com BioDiem to present at Hong Kong biotech
More informationWe have one of the World s Most Advanced Functional HIV Cures under development
Source : labiotech.eu, 04/07/2016 We have one of the World s Most Advanced Functional HIV Cures under development Abivax has recently announced that it s likely that its most advanced program in hepatitis
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s Means Swollen Liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationGENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE
GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S.
More informationFor personal use only
ACN 090 987 250 ASX Release SUDA LTD: INVESTOR PRESENTATION PERTH, AUSTRALIA 25 February 2016: SUDA LTD (ASX: SUD), a leader in oro- mucosal drug delivery, today announces that Mr. Stephen Carter, Chief
More informationForward Looking Statements
March 12, 2015 1 Forward Looking Statements This presenta5on contains forward- looking statements within the meaning of the Private Securi5es Li5ga5on Reform Act of 1995 that involve substan5al risks and
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) JUNE 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) JUNE 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cau7ons you that statements in this presenta7on that are not a descrip7on of historical
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationNOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation
Date 8 August 2017 Sydney, Australia ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operations Office: Suite 3 Level 4 828 Pacific
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationInvestor Presentation February 6, 2015
Investor Presentation February 6, 2015 Forward-Looking Statements Certain statements contained in this presenta0on cons0tute forward- looking informa0on within the meaning of securi0es laws. Forward- looking
More informationDigital healthcare for respiratory disease
Digital healthcare for respiratory disease Tony Kea)ng Chief Execu)ve Officer and Managing Director tony@resapphealth.com.au Canary Biotech & Healthcare Investor Roadshow 25 November 2015, Melbourne 26
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationGreg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia
NICE PBAC PBS CADTH Access Challenges Greg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia Disclaimer: The views expressed in this presenta5on are those of the author not his employer
More information5 December 2016 AIM: RENE. ReNeuron Group plc ( ReNeuron or the Company ) Reports positive results in Phase II stroke trial
5 December 2016 AIM: RENE ReNeuron Group plc ( ReNeuron or the Company ) Reports positive results in Phase II stroke trial ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
More informationWHO posi)on paper on hepa))s A vaccines
WHO posi)on paper on hepa))s A vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 13 July 2012 Transmission and incidence Hepa))s A virus (HAV) is transmiled primarily via the
More informationHEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015
HEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015 Overview Understand the GLOBAL and US burden of chronic HCV infec
More informationPhylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies
Phylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies Disclaimer The purpose of the presentation is to provide an
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationJefferies Global Life Sciences Conference June 2010
Jefferies Global Life Sciences Conference June 2010 Cautionary Statement This presentation contains "forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationCross border preparedness and response: Key health issues and challenges
Cross border preparedness and response: Key health issues and challenges Prince Mahidol Award Conference Bangkok, Thailand February 1, 2013 Prof. Mahmudur Rahman, PhD Director Ins/tute of Epidemiology,
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationFor personal use only
ASX: LCT - OTCQX: LVCLY Diabetes Neurodegenerative Diseases Cell Encapsulation Consolidation & Acceleration CEO REPORT AGM 2012 SAFE HARBOR STATEMENT This document contains certain forward-looking statements,
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationWHO posi)on paper on influenza vaccines*
WHO posi)on paper on influenza vaccines* Geneva, Switzerland Published in the Weekly Epidemiological Record on 23 November 2012 * This posi(on paper is concerned mainly with vaccines and vaccina(on against
More informationWHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012
WHO posi)on paper on pneumococcal vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines, April 2012 The current posi)on paper
More informationIMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016
Where did we start? Where did we get to? Where do we want to go? IMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016 Mar6na Penazzato Paediatric advisor HIV Department WHO, Geneva-
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationFind out more at: OUR MISSION
Find out more at: www.gilead.com/yir2017 SCIENTIFIC INNOVATION & ADDRESSING UNMET NEEDS Gilead uses its scientific expertise to help transform and simplify care for people with life-threatening illnesses
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s means swollen liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationInvestor Presentation May 2016
Investor Presentation May 2016 Forward Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forwardlooking statements as that term is defined
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationActivities in 2010, Priorities for 2011
European Centre for Disease Prevention and Control Activities in 2010, Priorities for 2011 Presentation to ENVI Committee by Marc Sprenger, Director ECDC 27 October 2010 Part 1: Examples of ECDC s work
More informationChairman s Address Dr. Richard Treagus
Chairman s Address Dr. Richard Treagus Annual Shareholders Meeting Of Neuren Pharmaceuticals Limited, 30 April 2014 Good morning Ladies and Gentlemen. Welcome to our Annual Shareholders Meeting in Melbourne.
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationDebate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collabora@ng Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationAnnual General Meeting
Annual General Meeting November 2017 ASX: MEB OTCQB: MDBIF Medibio Limited 2016 2 DISCLAIMER FORWARD LOOKING STATEMENTS Accordingly, these slides and the information they contain should be read in conjunction
More informationA New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study
A New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study A Collabora)on of the Medical Device Innova)on Consor)um, FDA, MIT, RTI
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationVivaGel Study Demonstrates Reduced Risk of Recurrent BV
VivaGel Study Demonstrates Reduced Risk of Recurrent BV KEY POINTS: 1% VivaGel demonstrated reduced risk of recurrent BV and delayed time to first recurrence in a Phase 2 study Several efficacy measures
More informationDrug delivery through the oral mucosa. Stephen Carter Chief Execu;ve Officer Nick Woolf Chief Business Officer. April 2014
Drug delivery through the oral mucosa Stephen Carter Chief Execu;ve Officer Nick Woolf Chief Business Officer April 2014 Overview SUDA (ASX: SUD) is a drug delivery company commercialising lowrisk pharmaceu>cals
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationSofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine
More informationMichael Levy Australian National University
Treatment is Prevention Do not under-estimate the importance of prevention as the key to treatment Michael Levy Australian National University The Burden World Health Assembly (2014) 1.4 million deaths
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationFor personal use only
ASX:NRT NASDAQ:NVGN Novogen Ltd (Company) MARKET RELEASE 12 September 2016 NOVOGEN PRESENTS AT RODMAN & RENSHAW CONFERENCE ABN 37 063 259 754 Capital Structure Ordinary Shares on issue: 429 M Board of
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationTuberculosis: What's new in diagnos6cs and management?
Tuberculosis: What's new in diagnos6cs and management? Colin Menezes, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand. Objec6ves of this talk:
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationAction plan for the health sector response to viral hepatitis in the WHO European Region
Action plan for the health sector response to viral hepatitis in the WHO European Region Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Albania Country Meeting: Tirana, 27-28 October 2016 Chronic
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationCHLAMYDIA, GONORRHEA & SYPHILIS: STDS ON THE RISE
CHLAMYDIA, GONORRHEA & SYPHILIS: STDS ON THE RISE What are sexually transmitted diseases (STDs)? Sexually transmitted diseases (STDs) are passed from person to person through sexual activity. These infections
More informationInterim Results for 6 Months Ended 31 March 2017 and Business Update. 17 th May 2017
Interim Results for 6 Months Ended 31 March 2017 and Business Update 17 th May 2017 Forward-looking Statements Please Note This presentation includes forward-looking statements. These forward-looking statements
More information